These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 25833208)

  • 1. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
    Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
    Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
    Pham E; Birrer MJ; Eliasof S; Garmey EG; Lazarus D; Lee CR; Man S; Matulonis UA; Peters CG; Xu P; Krasner C; Kerbel RS
    Clin Cancer Res; 2015 Feb; 21(4):808-18. PubMed ID: 25524310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
    Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
    Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
    Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
    Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
    Voss MH; Hussain A; Vogelzang N; Lee JL; Keam B; Rha SY; Vaishampayan U; Harris WB; Richey S; Randall JM; Shaffer D; Cohn A; Crowell T; Li J; Senderowicz A; Stone E; Figlin R; Motzer RJ; Haas NB; Hutson T
    Ann Oncol; 2017 Nov; 28(11):2754-2760. PubMed ID: 28950297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
    Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
    Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
    Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
    Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
    Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
    Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
    Gaur S; Wang Y; Kretzner L; Chen L; Yen T; Wu X; Yuan YC; Davis M; Yen Y
    Nanomedicine; 2014 Oct; 10(7):1477-86. PubMed ID: 24768630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
    Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
    J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
    Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
    Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Krasner CN; Campos SM; Young CL; Chadda KR; Lee H; Birrer MJ; Horowitz NS; Konstantinopoulos PA; D'Ascanio AM; Matulonis UA; Penson RT
    Gynecol Oncol; 2021 Sep; 162(3):661-666. PubMed ID: 34243976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
    Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
    Harrison H; Rogerson L; Gregson HJ; Brennan KR; Clarke RB; Landberg G
    Cancer Res; 2013 Feb; 73(4):1420-33. PubMed ID: 23248117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models.
    Schmidt KT; Chau CH; Strope JD; Huitema ADR; Sissung TM; Price DK; Figg WD
    Mol Cancer Ther; 2021 May; 20(5):915-924. PubMed ID: 33632874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.